Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438330 | 1.00 | MAPK1 (0.38) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL21875761 | 1.00 | MAPK1 (0.38) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL20621761 | 0.89 | KDM4C (0.37) | CNR2LMNATP53P2RX7PKM | |
| SCHEMBL21875787 | 0.88 | MAPK1 (0.41) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL29438302 | 0.88 | MAPK1 (0.41) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL29964976 | 0.88 | MAPK1 (0.41) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL21875780 | 0.88 | MAPK1 (0.40) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL29438298 | 0.88 | MAPK1 (0.40) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL29964854 | 0.88 | MAPK1 (0.40) | MAPK1CNR2BRD4CREBBPLMNA | |
| SCHEMBL21875807 | 0.87 | MAPK1 (0.40) | MAPK1BRD4CREBBPP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485733-B2 | Azaquinoline derivatives | RECQL, H1-5, H1-3 | MAPK1 4432/4885CNR2 804/4885BRD4 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.